Dow Jones
31.928,62 +48,38 (+0,15%) Nasdaq
11.264,45 -270,83 (-2,35%) Nikkei 225
26.748,14 -253,38 (-0,94%) EUR/USD
1,0737 -0,0001 (-0,01%) BTC-EUR
27.609,40 +271,48 (+0,99%) CMC Crypto 200
655,31 -0,52 (-0,08%)
OncoCyte Corporation (0KCC.L)
| Chiusura precedente | 1,1700 |
| Aperto | 1,0193 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 1,0193 - 1,0193 |
| Intervallo di 52 settimane | 1,0193 - 1,0193 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 92,816M |
| Beta (5 anni mensile) | 1,87 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,7710 |
| Prossima data utili | 08 ago 2022 - 12 ago 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Oncocyte Reports First Quarter 2022 Financial Results
IRVINE, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today reports financial results for the first quarter 2022, ended March 31, 2022. First Quarter and Recent Highlights: Reported total revenue of $1.4 million in the first quarter of 2022, compared with $1.1 million in the first quarter
- GlobeNewswire
Oncocyte Completes Validation of TheraSure™ Transplant Monitor Test
Digital PCR format allows for rapid turnaround time to facilitate fast and accurate post-transplant treatment decisionsIRVINE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that it has completed development of its proprietary TheraSure™ Transplant Monitoring test for liver
- GlobeNewswire
Oncocyte to Announce First Quarter 2022 Financial Results
IRVINE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, announced today that it will release its first quarter 2022 financial results on Wednesday, May 11, 2022. In conjunction with the release, Oncocyte will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m
